MEDI 3902

Drug Profile

MEDI 3902

Alternative Names: Anti-Psl/PcrV; MEDI3902

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator MedImmune
  • Class Antibacterials; Bispecific antibodies; Monoclonal antibodies
  • Mechanism of Action Bacterial polysaccharide inhibitors; PcrV inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Nosocomial pneumonia

Most Recent Events

  • 01 Mar 2016 Phase-II clinical trials in Nosocomial pneumonia (Prevention, In adults, In the elderly) in France (IV) (NCT02696902)
  • 19 Jan 2016 MedImmune plans a phase II trial for Nosocomial pneumonia (Prevention) in USA
  • 01 Apr 2015 MedImmune completes a phase I trial in healthy volunteers for the prevention of Nosocomial pneumonia in USA (NCT02255760)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top